Do oncologists have an incentive to prescribe expensive treatments?
A recent economic analysis concluded that patients with metastatic cancer value their treatments significantly more than regulators recognize, with many expensive new therapies looking like veritable bargains to most patients. Yet the study ignored the values really driving oncology spending—the warped incentives oncologists have to promote their own bottom line by prescribing expensive treatments.
Let’s start with the economic analysis, another in a series of studies by a USC team of …